https://www.prognyx.com/blog/fda-expands-immunitybio-s-anktiva-label-to-papillary-only-nmibcPrognyxen2026-10-15FDA expands ImmunityBio's Anktiva label to papillary-only NMIBC https://www.prognyx.com/blog/gilead-pays-vir-90m-upfront-for-three-masked-t-cell-engagers-in-solid-tumorsPrognyxen2026-10-14Gilead pays Vir $90M upfront for three masked T-cell engagers in solid tumors